Market Research Report
Western Equine Encephalitis - Pipeline Review, H2 2017
|Published by||Global Markets Direct||Product code||321911|
|Published||Content info||27 Pages
|Western Equine Encephalitis - Pipeline Review, H2 2017|
|Published: December 29, 2017||Content info: 27 Pages||
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Western Equine Encephalitis - Pipeline Review, H2 2017, provides an overview of the Western Equine Encephalitis (Infectious Disease) pipeline landscape.
Western equine encephalitis is a disease that is spread to humans by infected mosquitoes. Western equine encephalitis is caused by the western equine encephalitis virus, an arbovirus. Symptoms range from mild to severe and may include only fever and headache to encephalitis with delirium, disorientation or coma.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Western Equine Encephalitis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Western Equine Encephalitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Western Equine Encephalitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Western Equine Encephalitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 4 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.
Western Equine Encephalitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.